CN112010807A - 一种光敏剂及其用途和制备方法 - Google Patents
一种光敏剂及其用途和制备方法 Download PDFInfo
- Publication number
- CN112010807A CN112010807A CN201910455655.0A CN201910455655A CN112010807A CN 112010807 A CN112010807 A CN 112010807A CN 201910455655 A CN201910455655 A CN 201910455655A CN 112010807 A CN112010807 A CN 112010807A
- Authority
- CN
- China
- Prior art keywords
- photosensitizer
- cancer
- photodynamic therapy
- reaction raw
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003504 photosensitizing agent Substances 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 238000002428 photodynamic therapy Methods 0.000 claims abstract description 22
- 201000011510 cancer Diseases 0.000 claims abstract description 21
- 238000001959 radiotherapy Methods 0.000 claims abstract description 17
- 230000002776 aggregation Effects 0.000 claims abstract description 6
- 238000004220 aggregation Methods 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 32
- 238000006243 chemical reaction Methods 0.000 claims description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 19
- 230000002165 photosensitisation Effects 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 14
- 239000013067 intermediate product Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 210000003463 organelle Anatomy 0.000 claims description 8
- 239000011541 reaction mixture Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 238000010898 silica gel chromatography Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 230000001678 irradiating effect Effects 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 231100001083 no cytotoxicity Toxicity 0.000 claims 1
- 238000003384 imaging method Methods 0.000 abstract description 9
- 238000002648 combination therapy Methods 0.000 abstract description 4
- 208000017983 photosensitivity disease Diseases 0.000 abstract description 4
- 231100000434 photosensitization Toxicity 0.000 abstract description 4
- 238000011275 oncology therapy Methods 0.000 abstract description 2
- 239000000975 dye Substances 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 101100377855 Artemia franciscana ABDA gene Proteins 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 238000000942 confocal micrograph Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- YQNRLXWQEVPAAO-UHFFFAOYSA-N indeno[2,1-c]pyridin-1-one Chemical compound C1=CC=C2C3=CC=NC(=O)C3=CC2=C1 YQNRLXWQEVPAAO-UHFFFAOYSA-N 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000006617 triphenylamine group Chemical group 0.000 description 2
- BILFFOVZIVNIBJ-UHFFFAOYSA-N CC(C(=O)O)(C(=O)O)C.C1=CC=CC2=CC3=CC=CC=C3C=C12 Chemical compound CC(C(=O)O)(C(=O)O)C.C1=CC=CC2=CC3=CC=CC=C3C=C12 BILFFOVZIVNIBJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- OREAFAJWWJHCOT-UHFFFAOYSA-N dimethylmalonic acid Chemical compound OC(=O)C(C)(C)C(O)=O OREAFAJWWJHCOT-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- -1 saturated potassium hexafluorophosphate Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
- C09K2211/1033—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom with oxygen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02B—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO BUILDINGS, e.g. HOUSING, HOUSE APPLIANCES OR RELATED END-USER APPLICATIONS
- Y02B20/00—Energy efficient lighting technologies, e.g. halogen lamps or gas discharge lamps
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提出了一种光敏剂及其用途和制备方法。该光敏剂包括含三苯胺氮杂芴酮基团的光敏作用分子,具有聚集诱导发光性质,能够实现成像诱导的光动力治疗癌症,以及光动力治疗和放疗结合治疗癌症。
Description
技术领域
本发明涉及材料领域,尤其涉及一种光敏剂及其用途和制备方法,该光敏剂包括含三苯胺氮杂芴酮基团的光敏作用分子,具有聚集诱导发光性质,能够实现成像诱导的光动力治疗癌症,以及光动力治疗和放疗结合治疗癌症。
背景技术
传统的化疗和放疗具有严重的副作用,并且,癌细胞会对药物和辐射有抵抗,这些因素共同导致传统化疗和放疗的治疗效果不理想,癌症容易复发。在这种情况下,医疗研究机构进行了深入的研究,提出了一种光动力治疗。
光动力治疗的作用机制是:在光照下通过光敏剂产生活性氧,从而引发癌细胞的凋亡或者坏死,达到治疗癌症的目的。相比传统的治疗方法,光动力治疗具有很多优点,具体地,具有高时空精度、无创性、可控性、低毒性和无初始抗性的可重复处理等特性;这样,光动力治疗在治疗各种实体肿瘤(如皮肤,食道和肺)的临床应用中越来越受到关注。
然而,目前的光敏剂在光动力治疗上的效率不太高。
发明内容
本发明针对以上技术问题,提供一种光敏剂及其用途和制备方法。
本发明所提出的技术方案如下:
本发明提出了一种光敏剂,包括光敏作用分子,所述光敏作用分子的化学结构式为:
其中,R1采用以下基团中的任意一种:
n为1、2、3、4、5、6或7;
R2采用以下基团中的任意一种:
本发明上述的光敏剂中,R1为含氮的中性基团,R2为含氮的中性或者离子化基团。
本发明还提出了一种如上所述的光敏剂的用途,为光动力治疗癌症。
本发明上述的光敏剂的用途中,光动力治疗癌症的用途通过光敏剂的聚集诱导发光性质实现。
本发明上述的光敏剂的用途中,光敏作用分子具有细胞相容性,且没有细胞暗毒性,用于进入细胞。
本发明上述的光敏剂的用途中,光敏作用分子具有细胞器靶向能力,用于特异性靶向癌细胞的线粒体,溶酶体或者细胞膜等细胞器。
本发明上述的光敏剂的用途中,光敏作用分子在功率大于4mW/cm2的白光(400-1000nm)灯或者特定波长的激光照射下,产生大量活性氧,用于导致癌细胞死亡。
本发明上述的光敏剂的用途中,为采用光动力治疗和放疗的结合疗法治疗癌症。
本发明还提出了一种光敏剂的制备方法,包括以下步骤:
步骤S1、将第一反应原料和含有R1的第二反应原料混合,并一起加热至60℃-100℃,然后在保持温度的情况下连续光照18h-30h,再经冷却,分离,纯化,得到中间产物;
其中,第一反应原料的化学结构式为:
R1采用以下基团中的任意一种:
其中,n为1、2、3、4、5、6或7;
步骤S2、将中间产物与含有R2的第三反应原料反应,从而得到光敏剂;
其中,R2采用以下基团中的任意一种:
本发明上述的制备方法中,第二反应原料采用吗啉;
在步骤S1中,将第一反应原料和吗啉溶解在乙腈中并在双颈圆底烧瓶中混合,然后在干燥空气条件下搅拌加热至80℃,并用大于7W的LED荧光灯泡连续照射24h;反应结束后,冷却至室温,减压蒸馏除去溶剂,再通过硅胶柱色谱法进一步分离纯化,从而得到中间产物。
本发明提供了一种光敏剂及其用途和制备方法,该光敏剂包括含三苯胺氮杂芴酮基团的光敏作用分子,具有聚集诱导发光性质,能够实现成像诱导的光动力治疗癌症,以及光动力治疗和放疗结合治疗癌症,具有如下有益效果:
1)三苯胺基团具有强的给电子性能,氮杂芴酮具有强的吸电子性能,使得合成的光敏作用分子具有分子内电荷转移特性,具有大的斯托克位移,利于荧光成像。且扭曲的分子结构使得分子具有聚集诱导发光性质,容易实现成像诱导的光动力治疗癌症。
2)光敏作用分子能够特异性靶向某一个细胞器,且在白光照下能够快速的产生活性氧,提高了光动力治疗的效率。
3)光敏作用分子还能够作为放疗增敏剂,提高放疗的效率,因而可以结合光动力治疗和放疗共同来治疗癌症。
附图说明
图1示出了本发明第一实施例所制备的TPAPy的质谱图;
图2示出了本发明第二实施例所制备的TPANPF6的质谱图;
图3示出了TPANPF6的单线态氧(活性氧)生成检测的结果图;
图4示出了在405nm的激发波长下先后经过TPANPF6和MTDR处理的宫颈癌细胞系HeLa细胞的共聚焦显微镜成像图;
图5示出了在633nm的激发波长下先后经过TPANPF6和MTDR处理的宫颈癌细胞系HeLa细胞的共聚焦显微镜成像图;
图6示出了图4所示的共聚焦显微镜成像图和图5所示的共聚焦显微镜成像图的融合图;
图7示出了含TPANPF6染料培养基孵育细胞30min后,光照射30min或60min;再在照射完成后,孔板全部避光置培养箱中孵育24h,用MTT法检测细胞存活率的结果示意图;
图8示出了将HeLa细胞铺板到35mm培养皿中,10d-14d后,用0.5%结晶紫染色的照片;
图9示出了将采用放疗处理的HeLa细胞铺板到35mm培养皿中,10d-14d后,用0.5%结晶紫染色的照片;
图10示出了将先后采用TPANPF6处理和光照处理的HeLa细胞铺板到35mm培养皿中,10d-14d后,用0.5%结晶紫染色的照片;
图11示出了将先后采用放疗处理和TPANPF6处理的HeLa细胞铺板到35mm培养皿中,10d-14d后,用0.5%结晶紫染色的照片;
图12示出了将先后采用放疗处理、TPANPF6处理和光照处理的HeLa细胞铺板到35mm培养皿中,10d-14d后,用0.5%结晶紫染色的照片;
图13示出了将先后采用放疗处理、TPANPF6处理、光照处理和NAC处理的HeLa细胞铺板到35mm培养皿中,10d-14d后,用0.5%结晶紫染色的照片。
具体实施方式
本发明提出了一种光敏剂,包括光敏作用分子,该光敏作用分子的化学结构式为:
其中,R1可以采用以下基团中的任意一种:
其中,n为1、2、3、4、5、6或7;
R2可以采用以下基团中的任意一种:
从化学结构式来看,光敏作用分子具有三苯胺氮杂芴酮基团,其中,三苯胺基团具有强的给电子性能,氮杂芴酮具有强的吸电子性能,使得合成的光敏剂分子具有分子内电荷转移特性,具有大的斯托克位移,利于荧光成像。且扭曲的分子结构使得分子具有聚集诱导发光性质,容易实现成像诱导的光动力治疗癌症。
进一步地,本发明还提出了一种光敏剂的制备方法,包括以下步骤:
步骤S1、将第一反应原料和含有R1的第二反应原料混合,并一起加热至60℃-100℃,然后在保持温度的情况下连续光照18h-30h,再经冷却,分离,纯化,得到中间产物;
其中,第一反应原料的化学结构式为:
R1可以采用以下基团中的任意一种:
其中,n为1、2、3、4、5、6或7;
步骤S2、将中间产物与含有R2的第三反应原料反应,从而得到光敏剂。
其中,R2可以采用以下基团中的任意一种:
进一步地,在上述技术方案中,第一反应原料和第二反应原料通常在有机溶剂中混合,在一定条件下,也可以直接混合。当第二反应原料采用吗啉时,有机溶剂采用乙腈。这样,在步骤S1中,可以将第一反应原料和吗啉溶解在乙腈中并在双颈圆底烧瓶中混合,然后在干燥空气条件下搅拌加热至80℃,并用大于7W的LED荧光灯泡连续照射24h。反应结束后,冷却至室温,减压蒸馏除去溶剂,再通过硅胶柱色谱法进一步分离纯化,从而得到中间产物。
在步骤S2中,将中间产物与第三反应原料在氮气保护下溶于四氢呋喃中,加入催化剂和饱和碳酸钾溶液,发生化学反应得到光敏剂。
在这里,催化剂采用四(三苯基膦)钯,而光敏剂包括不同的光敏剂分子。光敏剂分子能够特异性靶向某一个细胞器,且在白光照下能够快速的产生活性氧,提高了光动力治疗的效率。同时,光敏剂分子还能够作为放疗增敏剂,提高放疗的效率,因而可以结合光动力治疗和放疗共同来治疗癌症。
为了使得发明的技术方案、技术目的以及技术效果更为清楚,以使得本领域技术人员能够理解和实施本发明,下面将结合附图及具体实施例对本发明做进一步详细的描述。
第一实施例
在本实施例中,光敏作用分子的化学结构式为:
本实施例还提出了上述光敏作用分子的制备方法,包括以下步骤:
1)TPABr的合成
将BDOYM-Br(0.5g,0.95mmol)、吗啉(0.082g,0.95mmol)和乙腈(MeCN)(20mL)在双颈圆底烧瓶中混合,然后一起在干燥空气条件下搅拌加热至80℃,并用7W荧光LED灯泡连续照射24h;反应结束后,冷却至室温,减压蒸馏除去溶剂。通过硅胶柱色谱法进一步分离纯化混合产物,得到橙红色固体目标产物(0.35g,产率为60%),即TPABr。1H NMR(d-DMSO,400MHz):δ8.25(d,1H),7.85(d,2H),7.77-7.73(m,1H),7.66-7.62(m,2H),7.53(d,2H),7.41-7.37(t,2H),7.20-7.13(m,3H),7.05(d,2H),6.96(d,2H),3.93-3.91(t,4H),3.76-3.74(t,4H).
2)TPAPy合成
在三颈圆底烧瓶中将TPABr(0.3g,0.49mmol),4-吡啶硼酸(0.074g,0.6mmol),四(三苯基膦)钯(0)(2.3mg,2μmol)溶解于脱气的THF(30mL)中。然后,在搅拌下将饱和碳酸钾溶液(7.2mL)加入到THF溶液中,得到混合物。混合物在氮气氛围下回流反应过夜,随后冷却至室温过滤,减压除去溶剂,得到粗产物。粗产物用二氯甲烷和盐水萃取三次,分离出有机相并用无水硫酸钠干燥,再通过硅胶柱色谱纯化,得到橙色固体产物(0.22g,产率为74%),即TPAPy。1H NMR(d-DMSO,400MHz):δ8.61(d,2H),8.30(d,1H),7.90(d,2H),7.82-7.79(m,3H),7.77-7.66(m,4H),7.45-7.41(t,2H),7.21-7.18(m,5H),7.05-7.03(d,2H),3.97-3.94(t,4H),3.78-3.76(t,4H).HRMS(MALDI-TOF)(m/z):[M]+calcd for C40H29N5O2,611.2321;found,611.2348,如图1所示。
第二实施例
在本实施例中,光敏作用分子的化学结构式为:
本实施例还提出了上述光敏作用分子的制备方法,包括以下步骤:
在氮气下将TPAN(0.2g,0.31mmol)和乙腈(5mL)在圆底烧瓶中混合;再加入碘甲烷(1mL),然后一起加热回流12h。反应结束后冷却至室温,倒入乙醚中,得到第一沉淀物。用丙酮重新溶解第一沉淀物,加入饱和的六氟磷酸钾(KPF6)溶液(5mL),得到混合物。将该混合物在室温下搅拌2h,反应完成后,减压蒸发丙酮,过滤出第二沉淀物,然后用水和乙醚洗涤。减压干燥得到产物(0.15g,产率为60%),即TPANPF6。1H NMR(d-DMSO,400MHz):δ8.32(d,1H),8.04(d,2H),7.93-7.89(t,4H),7.82-7.75(m,3H),7.71-7.66(m,2H),7.45-7.41(t,2H),7.23-7.20(m,5H),7.04(d,2H),3.98-3.96(t,4H),3.79-3.76(t,4H),3.63(s,9H).HRMS(MALDI-TOF)(m/z):[M]+calcd for C44H38F6N5O2P,813.2667;found,813.2647,calcdfor C44H38N5O2 +,668.3020;found,668.2864,如图2所示。
光敏剂的单线态氧(活性氧)生成检测(二亚甲基丙二酸蒽法)
二亚甲基丙二酸蒽(ABDA)用作单线态氧检测探针。在实验中,将10μL的ABDA母液(10mM)加入到2mL的TPANPF6染料悬浮液(10μM)中,并用白光(4.2mW/cm2)作为光照源。记录不同照射时间段ABDA在378nm处的吸收值,以获得光敏化过程其衰减速率,如图3所示。
光敏剂的细胞器共定位检测
1)将宫颈癌细胞系HeLa细胞与10μM TPANPF6孵育30min。除去染料培养基并用PBS轻柔洗涤3次;
2)添加细胞器成像的商业染料,以用于细胞共定位成像分析。商业染料是:线粒体染料MitoTracker Deep Red(MTDR,50nM),孵育30min;
3)PBS洗3次。共聚焦显微镜成像并分析。MTDR,激发波长633nm,发射滤光片为690nm-750nm。TPANPF6,激发波长:405nm;发射滤光片:520-650nm;结果如图4-图6所示。
光动力治疗效率检测
在96孔板中铺好细胞,过夜。含TPANPF6染料培养基孵育细胞30min(避光放置培养箱中,37℃)后,光照射30min或60min。照射完成后,孔板全部避光置培养箱中孵育24h,用MTT法检测细胞存活率,结果如图7所示。
光动力治疗和放疗结合治疗检测
利用细胞集落形成实验检测,用不同处理对HeLa细胞进行处理,然后收集并重新铺板到35mm培养皿中。10d-14d后,用0.5%结晶紫染色细胞,结果如图8-图13所示。
上面结合附图对本发明的实施例进行了描述,但是本发明并不局限于上述的具体实施方式,上述的具体实施方式仅仅是示意性的,而不是限制性的,本领域的普通技术人员在本发明的启示下,在不脱离本发明宗旨和权利要求所保护的范围情况下,还可做出很多形式,这些均属于本发明的保护之内。
Claims (10)
2.根据权利要求1所述的光敏剂,其特征在于,R1为含氮的中性基团,R2为含氮的中性或者离子化基团。
3.一种如权利要求1或2所述的光敏剂的用途,其特征在于,为光动力治疗癌症。
4.根据权利要求3所述的光敏剂的用途,其特征在于,光动力治疗癌症的用途通过光敏剂的聚集诱导发光性质实现。
5.根据权利要求3所述的光敏剂的用途,其特征在于,光敏作用分子具有细胞相容性,且没有细胞暗毒性,用于进入细胞。
6.根据权利要求3所述的光敏剂的用途,其特征在于,光敏作用分子具有细胞器靶向能力,用于特异性靶向癌细胞的细胞器。
7.根据权利要求3所述的光敏剂的用途,其特征在于,光敏作用分子在功率大于4mW/cm2的白光灯或者特定波长的激光照射下,产生大量活性氧,用于导致癌细胞死亡。
8.根据权利要求3所述的光敏剂的用途,其特征在于,为采用光动力治疗和放疗的结合疗法治疗癌症。
10.根据权利要求9所述的制备方法,其特征在于,第二反应原料采用吗啉;
在步骤S1中,将第一反应原料和吗啉溶解在乙腈中并在双颈圆底烧瓶中混合,然后在干燥空气条件下搅拌加热至80℃,并用大于7W的LED荧光灯泡连续照射24h;反应结束后,冷却至室温,减压蒸馏除去溶剂,再通过硅胶柱色谱法进一步分离纯化,从而得到中间产物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910455655.0A CN112010807B (zh) | 2019-05-29 | 2019-05-29 | 一种光敏剂及其用途和制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910455655.0A CN112010807B (zh) | 2019-05-29 | 2019-05-29 | 一种光敏剂及其用途和制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112010807A true CN112010807A (zh) | 2020-12-01 |
CN112010807B CN112010807B (zh) | 2022-04-26 |
Family
ID=73501552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910455655.0A Active CN112010807B (zh) | 2019-05-29 | 2019-05-29 | 一种光敏剂及其用途和制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112010807B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115960042A (zh) * | 2022-12-30 | 2023-04-14 | 中山大学 | 一种3-(二氰基亚甲基)茚-1-酮修饰的2-苯基吡啶衍生物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106565606A (zh) * | 2016-10-17 | 2017-04-19 | 华南理工大学 | 具有聚集诱导发光性质的化合物及其制备方法和用途 |
CN109970630A (zh) * | 2019-04-23 | 2019-07-05 | 四川大学 | 一种能靶向线粒体的双光子荧光探针及其制备方法和应用 |
-
2019
- 2019-05-29 CN CN201910455655.0A patent/CN112010807B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106565606A (zh) * | 2016-10-17 | 2017-04-19 | 华南理工大学 | 具有聚集诱导发光性质的化合物及其制备方法和用途 |
CN109970630A (zh) * | 2019-04-23 | 2019-07-05 | 四川大学 | 一种能靶向线粒体的双光子荧光探针及其制备方法和应用 |
Non-Patent Citations (5)
Title |
---|
MEHTAP TUGRAK等: "New azafluorenones with cytotoxic and carbonic anhydrase inhibitory properties: 2-Aryl-4-(4-hydroxyphenyl)-5H-indeno[1,2-b]pyridin-5-ones", 《BIOORGANIC CHEMISTRY》 * |
MENG GAO等: "Photoactivatable aggregation-induced emission probes for lipid droplets-specific live cell imaging", 《CHEMICAL SCIENCE》 * |
ZHENGZE YU等: "A Near-Infrared Triggered Nanophotosensitizer Inducing Domino Effect onMitochondrial Reactive Oxygen Species Burst for Cancer Therapy", 《ACS NANO》 * |
蒋昕鹏,等: "光动力活性氧的研究进展", 《科学通报》 * |
许敏,等: "聚集诱导发光分子在光动力治疗中的研究进展", 《分析测试学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115960042A (zh) * | 2022-12-30 | 2023-04-14 | 中山大学 | 一种3-(二氰基亚甲基)茚-1-酮修饰的2-苯基吡啶衍生物及其制备方法和应用 |
CN115960042B (zh) * | 2022-12-30 | 2024-03-29 | 中山大学 | 一种3-(二氰基亚甲基)茚-1-酮修饰的2-苯基吡啶衍生物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112010807B (zh) | 2022-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109970630B (zh) | 一种能靶向线粒体的双光子荧光探针及其制备方法和应用 | |
Güzel et al. | Synthesis, characterization and photodynamic activity of a new amphiphilic zinc phthalocyanine | |
Choi et al. | Glycosylated zinc (II) phthalocyanines as efficient photosensitisers for photodynamic therapy. Synthesis, photophysical properties and in vitro photodynamic activity | |
Karges et al. | A Ru (II) polypyridyl complex bearing aldehyde functions as a versatile synthetic precursor for long-wavelength absorbing photodynamic therapy photosensitizers | |
CN108503658A (zh) | 一种近红外氯化氮杂氟硼烷染料及其制备方法和应用 | |
CN104861039B (zh) | 一种酞菁基化合物、制备方法及作为单、双光子荧光探针在癌症靶向及线粒体标记中的应用 | |
CN113861156B (zh) | 近红外聚集诱导发光有机荧光染料及其制备方法与应用 | |
CN112094263B (zh) | 基于喹喔啉的D-A-π-A型有机光敏剂及其合成方法和应用 | |
CN111662333A (zh) | 一类双三联吡啶铱(ⅲ)配合物及其合成方法 | |
CN109575061A (zh) | 一种水溶性的抗癌光敏剂及其制备和应用 | |
Ma et al. | Enhanced singlet oxygen generation of a soft salt through efficient energy transfer between two ionic metal complexes | |
CN114621290B (zh) | 一种不同空间结构的磷咔咯化合物及其制备方法与应用 | |
CN114591632B (zh) | 一类氮杂吲哚-半花菁染料、其合成方法及应用 | |
CN112010807B (zh) | 一种光敏剂及其用途和制备方法 | |
CN115232145A (zh) | 一种aie型有机光敏剂及其合成方法和应用 | |
CN113200913B (zh) | 一种光激活i型光敏剂及其制备方法和应用 | |
CN108503673B (zh) | 一种近红外氮杂吡咯烷染料及其制备方法和应用 | |
CN111548373B (zh) | 铱配氮杂吡咯烷酮光诊疗试剂及其制备方法与应用 | |
CN108358972B (zh) | 邻菲罗啉钌配合物类光敏染料及其制备方法和用途 | |
CN113480528B (zh) | 一种专一靶向线粒体且高效产生单线态氧的咪唑类光敏剂及其制备方法 | |
CN113501836A (zh) | 一种星型bodipy近红外荧光染料及其制备方法 | |
CN116836565B (zh) | 一类水溶性方酸菁染料及其合成方法和应用 | |
CN114773875B (zh) | 一类氮杂吲哚-方酸菁染料,其合成方法及应用 | |
CN109810538B (zh) | 一种线粒体定位染料及其制备方法和应用 | |
CN111423402B (zh) | 一类聚集诱导发光型近红外荧光材料及其合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |